



J M Nabholz

Contact

J M Nabholz

Publications (4)

Thürlimann B, Robertson J, Nabholz J, Buzdar A, Bonneterre J, Arimidex Study Group. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. *European journal of cancer (Oxford, England : 1990)* 2003; 39:2310-7.

Nabholz J, Bonneterre J, Buzdar A, Robertson J, Thürlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. *European journal of cancer (Oxford, England : 1990)* 2003; 39:1684-9.

Bonneterre J, Arimidex Writing Committee, Steinberg M, Webster A, Sahnoud T, von Euler M, Thürlimann B, Robertson J, Nabholz J, Buzdar A, Investigators Committee Members. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. *Cancer* 2001; 92:2247-58.

Nabholz J, Murawsky M, Alaki M, Apro M, Drbal J, Trillet-Lenoir V, Rosso R, Rapoport B, Vandenberg T, Douma J, Deschênes L, Melnychuk D, Bezwoda W, Thürlimann B, Riva A. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer. *Oncology (Williston Park, N.Y.)* 1997; 11:25-30.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch